Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza to make Bluebird Bio drugs

by Ann M. Thayer
June 20, 2016 | A version of this story appeared in Volume 94, Issue 25

Lonza has agreed to manufacture future commercial supplies of two lentiviral-based gene therapies for Bluebird Bio, a developer of drugs for genetic diseases and T cell-based immunotherapies for cancer. The two companies already have a multiyear relationship for clinical-scale materials. Now Lonza will build a dedicated production suite at its facility near Houston. The 9,300 m2 site, set to be completed in 2017, is designed to produce viral vectors and virally-modified cell therapy products using single-use bioreactors.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.